Groups most effected by COVID-19

Relatively speaking how will different groups fair this summer? Specifically how will groups such as LevFin, HC, and FIG perform relative to the others? I am asking with regards to this upcoming summer and into 2021 if you think it's applicable.

30 Comments
 

Still active, probably not much less than normal. Have not heard of any cuts or shocking declining deal flow from any banks for this group. I think March was tough for everyone but the rebound was fairly easy and expected.

Dayman?
 

I work in consumer M&A and it's been pretty fucked but starting to improve a bit. Businesses that have an e-commerce angle, are in food & bev (through retail) and consumer health are doing solid and will come to market soon depending on debt market conditions. Investors want to put money to work so it's really a question of leverage and if good businesses are going to take a multiple hit because of COVID.

However, most other parts of consumer have been hit hard and are going to wait 6-12 months to see where they are at before they consider an exit. A lot of them will want a full year of post-COVID financials so they don't need to defend some crazy adjustments (outside of the normal aggressive add-backs we apply). Obviously, they also want the business to be stable going into a sale process.

 
Most Helpful

Curious about folks thoughts on this as well. Smaller community banks are going to get crushed in the coming months as a good amount of small / medium sized local businesses inevitably default, not to mention community banks in the South that are heavily exposed to O&G... wonder if this will spur some M&A by larger banks.

For insurance, there will be a ton of corona related claims, which can only hurt profitability. I wonder if this would increase IB activity as a FIG banker or decrease it?

 

Don’t work in a tech group but have a lot of friends at software companies. They are seeing a lot of customer churn with subscriptions being cancelled / frozen, no new deals, etc. For startups that were relying on series funding to drive growth - there will definitely be near-term liquidity constraints & layoffs which will put a hamper on overall growth trajectory and future funding

 

Don't agree - HY / non-IG financing relies a lot more on spreads than the underlying base rates. A leveraged loan has spreads of several hundred basis points above a reference rate - those spreads have widened more than reference rates have come down. LevFin may take a long time to get going again, depending on what defaults in the space look like. Energy is also a core part of HY issuance and they're not in the best shape as of now. M&A usually has RX roll in under them and companies may potentially be divesting assets to raise capital so I'd say that is for sure a safer bet than LevFin.

 

This is valid. Outlook for levfin probably going to be scary. But speaking with people in a strong levfin group, it seems like depending on the industry/company, there still seems to be robust activity going on.

Maybe the analogy to make is that it can be like RX. Everyone says that RX does well in downturns, but in economic booms "there's always a company that needs to restructure." Likewise, there's probably always a company that wants to try and issue or refi for whatever reason.

 

LevFins groups are not super busy. Primarily spending time on amendments / cov relief. Fees on those situations are half compared to general underwriting fees.

LevFin will be busy once sponsors feel assets are appropriately priced / sellers come to the realization that their assets are worth lower from pre-covid valuations.

Sponsors also need to account for OID. Secondary lev loan market is ~90. Ideally need it to be in the ~95 zipcode for effective issuance.

Gut feeling -will prob see traditional sponsor activity in late August / September.

 

Any insight as to what deal flow will look like for healthcare in the coming months (i.e summer and into the fall)?

 

I can only speak for EMEA: right now the only deals going through are those that could benefit somehow from Covid-19 situation (Dx, Pharma with potential treatments, hospital sterilisation, medical supplies, etc.) and the PE guys who are circling around publicly-listed companies who tanked (but have good fundamentals). Look, if you are looking for deal flow, go to an M&A team. You can then switch to a sector if you want. If you cannot, TMT, HC and FIG will always have deals right, left and centre.

 

Voluptatem eaque possimus rerum neque numquam. Consequatur error labore autem quia quos nulla aut. Voluptas quibusdam non eum et pariatur et. Omnis animi reprehenderit incidunt id quisquam. Voluptates nihil odio doloremque recusandae voluptas quo voluptatibus.

Accusamus placeat ea totam amet in quidem aperiam. Rerum quasi at eos consequatur quos eos accusantium. Provident et rerum sed enim. Ut quis harum autem qui et. Quo error corporis qui sequi quae voluptatem.

 

Saepe in aut fugit sed dicta magni non sapiente. At asperiores nemo minima molestias ea. Omnis vel neque possimus exercitationem inventore.

Sed similique ut libero dolorem impedit eum. Animi voluptate consequatur ut ratione. Aspernatur maxime et sit aut fuga soluta odio molestiae.

Ipsum laboriosam nulla aut cumque velit. In omnis voluptatem consectetur ut necessitatibus laudantium. Harum sed velit quis adipisci. Assumenda sed voluptas inventore dolore dolorum. Ducimus exercitationem reiciendis nemo ut ut. Qui non ut provident voluptas et veritatis ut. Deleniti ea corrupti omnis quo repellendus aut hic.

Qui necessitatibus quaerat ea et distinctio. Voluptate explicabo sit nihil laudantium nemo esse ex atque. Molestiae harum fuga assumenda quia rerum ipsam deserunt.

Career Advancement Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

July 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.9%
  • Morgan Stanley 01 98.3%
  • BMO Capital Markets 12 97.7%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.7%
  • JPMorgan 01 97.1%

Total Avg Compensation

July 2026 Investment Banking

  • Vice President (15) $434
  • Associates (46) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (79) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
Secyh62's picture
Secyh62
99.0
5
CompBanker's picture
CompBanker
98.9
6
DrApeman's picture
DrApeman
98.9
7
GameTheory's picture
GameTheory
98.9
8
dosk17's picture
dosk17
98.9
9
Betsy Massar's picture
Betsy Massar
98.9
10
numi's picture
numi
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”